The invention relates to the use of whey permeate,preferably sweet whey permeate and more preferablyhydrolysed or partially-hydrolysed sweet whey permeate forthe production of a pharmaceutical composition forprophylaxis or treatment of symptoms of metabolic syndrome,type-2 diabetes and secondary diseases, said compositionbeing provided for a mammal.